Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
BIAF
bioAffinity Technologies, Inc.
CyPath Lung testing is delivered as a laboratory testing service via Precision Pathology Laboratory Services (PPLS).
|
$1.38M |
$1.46
+2.10%
|
|
VYST
Vystar Corporation
RxAir medical-grade air purification devices and FDA-cleared units position the company in medical devices and biometrics.
|
$1.33M |
$0.08
|
|
GRTX
Galera Therapeutics, Inc.
Company directly develops oncology therapeutics, including its NOS pan-inhibitor and SOD mimetics for cancer indications.
|
$1.15M |
$0.02
|
|
AEMD
Aethlon Medical, Inc.
Hemopurifier is a blood purification device, the core product offering of Aethlon Medical.
|
$1.12M |
$4.29
+5.79%
|
|
AURX
Nuo Therapeutics, Inc.
Aurix System is a wound care device used for chronic wounds (direct product).
|
$972618 |
$2.18
|
|
CDT
CDT Equity Inc.
AZD1656/AZD5658 are small-molecule therapeutics licensed for development.
|
$792299 |
$2.09
+13.59%
|
|
WOK
WORK Medical Technology Group Ltd.
Company directly manufactures disposable medical device consumables sold globally (e.g., masks, breathing circuits, endotracheal tube holders).
|
$752550 |
$4.93
+13.33%
|
|
MYNZ
Mainz Biomed B.V.
PancAlert is a blood-based diagnostic test using biomarker panels (liquid biopsy) to detect pancreatic cancer, fitting the Liquid Biopsy investable theme.
|
$716424 |
$1.12
+12.01%
|
|
CMND
Clearmind Medicine Inc.
CMND-100 is an oral small-molecule therapeutic candidate, categorizing the company under Oral Small Molecule Therapeutics.
|
$617181 |
$0.15
-7.12%
|
|
INIS
International Isotopes Inc.
Core product: INIS manufactures radiopharmaceutical drugs (I-131) used for diagnostic imaging and therapy.
|
$580409 |
$0.06
|
|
MSPR
MSP Recovery, Inc.
Biometric technology used for patient verification and data integrity.
|
$504239 |
$0.36
-2.65%
|
|
WLDS
Wearable Devices Ltd.
Biometric authentication and biometric sensing features embedded in the Mudra platform align with Medical Devices & Biometrics.
|
$485633 |
$1.85
-3.14%
|
|
SLRX
Salarius Pharmaceuticals, Inc.
Salarius operates as a clinical-stage biotech focused on oncology therapies (e.g., LSD1 inhibitor seclidemstat) and develops cancer treatments.
|
$471478 |
$0.92
+4.23%
|
|
ZVSA
ZyVersa Therapeutics, Inc.
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, classifiable as Monoclonal Antibody Therapeutics.
|
$378551 |
$0.14
|
|
NLSP
NLS Pharmaceutics AG
Kadimastem's allogeneic cell-therapy platform (IsletRx, AstroRx) and NLSP's merger create a clear Cell Therapy business line.
|
$377531 |
$0.79
-74.81%
|
|
RGBP
Regen BioPharma, Inc.
Pipeline includes HemaXellarate, dCellVax, tCellVax, and DuroCAR, representing cell therapy modalities.
|
$306080 |
$0.01
|
|
TIRX
Tian Ruixiang Holdings Ltd
Core product is health insurance solutions enabled by AI-driven tech via Ucare platform.
|
$234417 |
$0.76
-6.58%
|
|
FCHS
First Choice Healthcare Solutions, Inc.
The company is pivoting to operate outpatient primary care clinics / ambulatory services led by nurse practitioners.
|
$197750 |
$0.01
|
|
LADX
LadRx Corporation
LadRx is a biotechnology company focused on oncology drug development.
|
$64362 |
$0.13
|
|
CERO
CERo Therapeutics Holdings, Inc.
CER-T is a cell therapy platform with lead candidate CER-1236, indicating direct cell-based therapeutic products.
|
$28861 |
$0.10
+38.00%
|
|
EMMA
Emmaus Life Sciences, Inc.
Endari is an oral small-molecule therapeutic (L-glutamine) marketed by Emmaus Life Sciences for sickle cell disease.
|
$13548 |
$0.01
|
|
PLRZ
Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
|
$8442 |
$0.52
-11.07%
|
|
SMFL
Smart for Life, Inc.
SMFL owns manufacturing facilities (BSNM and DSO) and provides contract manufacturing for branded and contract-made nutraceutical products.
|
$57 |
$0.02
|
|
NCNA
NuCana plc
NuCana is a clinical-stage oncology biotech focusing on cancer therapeutics (NUC-3373 and NUC-7738).
|
N/A |
$3.97
+3.12%
|
Showing page 38 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
